

Special Issue

Tailoring Treatment with Biomarkers: Advancements in Heart Failure Management

Message from the Guest Editors

In recent years, the integration of biomarkers into clinical practice has revolutionized our approach to understanding, diagnosing, and managing heart failure. The nuanced insights provided by biomarkers offer a personalized avenue for optimizing therapeutic interventions, ushering in a new era of precision medicine in cardiac care. The multifaceted nature of heart failure demands a tailored approach, acknowledging the inherent heterogeneity among patients. Biomarkers serve as indispensable tools, offering a deeper understanding of disease pathophysiology and aiding clinicians in navigating the complexities of individual patient profiles. This Special Issue focuses on the role of biomarkers in heart failure diagnosis, prognosis, and treatment. We invite researchers to submit original studies, as well as systematic reviews. State-of-the-art narrative reviews will also be considered for publication.

Guest Editors

Prof. Dr. John S. Skoularigis

Department of Cardiology, University Hospital of Larissa, Larissa, Greece

Dr. Andrew Xanthopoulos

Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece

Deadline for manuscript submissions

16 May 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/192208

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).